- SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy didn’t meet the first endpoints of progression-free survival at major evaluation and general survival at first interim evaluation
- The mixture of tiragolumab plus Tecentriq and chemotherapy confirmed decreased efficacy in comparison with the comparator arm
- Security was according to earlier research, nevertheless we intend to halt the trial attributable to decreased efficacy in comparison with the comparator arm
Basel, 04 July 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) introduced at the moment that the part II/III SKYSCRAPER-06 examine, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an preliminary (first-line) remedy for individuals with beforehand untreated, domestically superior unresectable or metastatic non-squamous non-small cell lung most cancers, didn’t meet its major endpoints of progression-free survival (PFS) at its major evaluation with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and general survival (OS) at its first interim evaluation with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. The mixture of tiragolumab plus Tecentriq and chemotherapy confirmed decreased efficacy in each PFS and OS in comparison with the comparator arm within the intent-to-treat inhabitants, which incorporates the part II and part III cohorts. The general security profile stays according to the security profile beforehand noticed for the mixture of tiragolumab plus Tecentriq and chemotherapy, and no new or sudden findings had been recognized. Based mostly on these outcomes, sufferers and investigators will likely be unblinded and we intend to halt the examine. A communication will likely be despatched to the investigators and outcomes will likely be shared with well being authorities and subsequently introduced at an upcoming medical assembly.
“These outcomes are disappointing because it was our hope that this mixture would possibly yield improved outcomes for individuals residing with metastatic non-squamous lung most cancers,” stated Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of World Product Growth. “We’re grateful to the entire sufferers and healthcare professionals concerned within the examine, and we’ll leverage the learnings to tell our scientific understanding of the anti-TIGIT pathway and new avenues in most cancers analysis.”
Ongoing part III research are investigating remedy settings and indications distinct from SKYSCRAPER-06. Based mostly on at the moment’s outcomes, we’ll consider any related adjustments wanted to the continuing tiragolumab programme.
About SKYSCRAPER-06 examine
SKYSCRAPER-06 is a worldwide part II/III, randomised, placebo-controlled and double-blinded examine evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy as an preliminary (first-line) remedy versus pembrolizumab and chemotherapy in 542 individuals with non-squamous non- small cell lung most cancers. Main endpoints are general survival (OS) and progression-free survival (PFS).
About tiragolumab
Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc area. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to most cancers. Based mostly on preclinical analysis, tiragolumab is assumed to work as an immune amplifier with different most cancers immunotherapies reminiscent of Tecentriq® (atezolizumab). The TIGIT pathway is distinct however complementary to the PD-L1/PD-1 pathway. Twin blockade with tiragolumab and Tecentriq might assist overcome immune suppression and restore the immune response.
About Tecentriq® (atezolizumab)
Tecentriq is a most cancers immunotherapy authorised for a few of the most aggressive and difficult-to-treat types of most cancers. Tecentriq was the primary most cancers immunotherapy authorised for the remedy of a sure kind of early-stage (adjuvant) non-small cell lung most cancers (NSCLC), small cell lung most cancers (SCLC) and hepatocellular carcinoma (HCC). Tecentriq can also be authorised in international locations all over the world, both alone or together with focused therapies and/or chemotherapies, for numerous types of metastatic NSCLC, sure sorts of metastatic urothelial most cancers (mUC), PD-L1-positive metastatic triple-negative breast most cancers (TNBC), BRAF V600 mutation-positive superior melanoma and alveolar gentle half sarcoma (ASPS).
Tecentriq is a monoclonal antibody designed to bind with a protein referred to as programmed dying ligand-1 (PD-L1), which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with each PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq might allow the activation of T-cells. Tecentriq is a most cancers immunotherapy that has the potential for use as a foundational mixture associate with different immunotherapies, focused therapies and numerous chemotherapies throughout a broad vary of cancers.
Along with intravenous infusion, Tecentriq has been authorised as a subcutaneous formulation in over 40 international locations. The authorised indications for Tecentriq SC mirror these of Tecentriq IV.
About Roche
Based in 1896 in Basel, Switzerland, as one of many first industrial producers of branded medicines, Roche has grown into the world’s largest biotechnology firm and the worldwide chief in in-vitro diagnostics. The corporate pursues scientific excellence to find and develop medicines and diagnostics for enhancing and saving the lives of individuals all over the world. We’re a pioneer in personalised healthcare and wish to additional rework how healthcare is delivered to have an excellent larger affect. To supply the very best take care of every individual we associate with many stakeholders and mix our strengths in Diagnostics and Pharma with information insights from the medical observe.
In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the crucial sustainable firms within the prescribed drugs business by the Dow Jones Sustainability Indices for the fifteenth consecutive yr. This distinction additionally displays our efforts to enhance entry to healthcare along with native companions in each nation we work.
Genentech, in the USA, is an entirely owned member of the Roche Group. Roche is almost all shareholder in Chugai Pharmaceutical, Japan.
For extra info, please go to www.roche.com.
All logos used or talked about on this launch are protected by legislation.
Roche World Media Relations
Telephone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Bushes, PhD Telephone: +41 79 407 72 58 |
Sileia Urech Telephone: +41 79 935 81 48 |
| Nathalie Altermatt Telephone: +41 79 771 05 25
|
Simon Goldsborough Telephone: +44 797 32 72 915
|
| Karsten Kleine Telephone: +41 79 461 86 83
|
Nina Mählitz Telephone: +41 79 327 54 74 |
| Kirti Pandey Telephone: +49 172 6367262
|
Yvette Petillon Telephone: +41 79 961 92 50 |
| Dr. Rebekka Schnell Telephone: +41 79 205 27 03 |
Roche Investor Relations
Investor Relations North America
